Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002020 · ClinicalTrials.gov registry record · NA

Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC

A NA study of HIV Infections, sponsored by Glaxo Wellcome.

Completed
Registry status
NA
Development phase
12
Study locations

NCT00002020: Completed NA study of HIV Infections, sponsored by Glaxo Wellcome.

NCT00002020 is a NA study of HIV Infections that has completed, run by Glaxo Wellcome. The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002020, a NA study of HIV Infections, has completed, sponsored by Glaxo Wellcome.

COMPLETED
Registry status
NA
Development phase
12
Study locations

Study Summary

To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine

Study Locations (12)

Illinois

  • Northwestern Univ Med School - Chicago
  • Cook County Hosp - Chicago
  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago

Texas

  • Univ TX Galveston Med Branch - Galveston
  • Baylor College of Medicine - Houston

Arizona

  • Univ of Arizona / Health Science Ctr - Tucson

Missouri

  • Univ of Missouri at Kansas City School of Medicine - Kansas City

New Jersey

  • North Jersey Community Research Initiative - Newark

New Mexico

  • Univ of New Mexico Hlth Sciences Ctr / Dept of Med - Albuquerque

New York

  • Northshore Hosp / Cornell Univ - Manhasset

Pennsylvania

  • Univ of Pennsylvania / HIV Clinic - Philadelphia

Trial Details

FieldValue
Phase NA
Glaxo Wellcome

65 total trials

What the finished NCT00002020 record still lists

NCT00002020 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Zidovudine is the first listed.

NCT00002020 lists 12 locations in 9 states (Illinois, Texas, Arizona).

Frequently Asked Questions

What is clinical trial NCT00002020 about?

NCT00002020 is a clinical study titled "Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC". To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours.

What is the current status of trial NCT00002020?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002020 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002020?

The interventions under investigation include: Zidovudine (DRUG).

Who is sponsoring clinical trial NCT00002020?

This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002020 being conducted?

This trial has 12 study locations across Arizona, Illinois, Missouri, New Jersey, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002020, the US trial registry maintained by the National Library of Medicine. NCT00002020 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.